000132852 001__ 132852
000132852 005__ 20240229105035.0
000132852 0247_ $$2doi$$a10.1097/DCR.0000000000001068
000132852 0247_ $$2pmid$$apmid:29624548
000132852 0247_ $$2ISSN$$a0012-3706
000132852 0247_ $$2ISSN$$a1530-0358
000132852 0247_ $$2altmetric$$aaltmetric:36282666
000132852 037__ $$aDKFZ-2018-00495
000132852 041__ $$aeng
000132852 082__ $$a150
000132852 1001_ $$0P:(DE-He78)3772dc9cbbc020fbc52b5f63f1dc1e96$$aPulte, Dianne$$b0$$eFirst author$$udkfz
000132852 245__ $$aDisparities in Colon Cancer Survival by Insurance Type: A Population-Based Analysis.
000132852 260__ $$aHagerstown, Md.$$bLippincott Williams & Wilkins$$c2018
000132852 3367_ $$2DRIVER$$aarticle
000132852 3367_ $$2DataCite$$aOutput Types/Journal article
000132852 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1660118592_22214
000132852 3367_ $$2BibTeX$$aARTICLE
000132852 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000132852 3367_ $$00$$2EndNote$$aJournal Article
000132852 520__ $$aColon cancer is a common cancer with a relatively high survival for nonmetastatic disease if appropriate treatment is given. A lower survival rate for patients with no or inadequate insurance has previously been documented, but the differences have not been explored in detail on a population level.The purpose of this study was to examine survival for patients with colon cancer by insurance type.Complete analysis was used to examine 1-, 2-, and 3-year survival rates.This was a population-level analysis.Patients were drawn from the in-patients diagnosed with colon cancer at ages 15 to 64 years between 2007 and 2012 in the Surveillance, Epidemiology, and End Results 18 database by insurance type (Medicaid, uninsured, or other insurance) MAIN OUTCOME MEASURE:: This study measured overall survival.A total of 57,790 cases were included, with insurance information available for 55,432. Of those, 7611 (13.7%), 4131 (7.5%), and 43,690 (78.8%) had Medicaid, no insurance, or other insurance. Patients with Medicaid or without insurance were more likely to have metastatic disease compared with those with other insurance. Survival was higher for patients with insurance other than Medicaid, with 3-year survival estimates of 57.0%, 61.2%, and 75.6% for Medicaid, uninsured, and other insurance. Significant disparities continued to be observed after adjustment for stage, especially for later-stage disease. When only patients with stage I to II disease who had definitive surgery and resection of ≥12 lymph nodes were included in the analysis, the discrepancy was decreased, especially for uninsured patients.Information on chemotherapy use and biological markers of disease severity are not available in the database.Colon cancer survival is lower for patients with no insurance or with Medicaid than for those with private insurance. Differences in rates of definitive surgery and adequate lymph node dissection explain some of this disparity. See Video Abstract at http://links.lww.com/DCR/A585.
000132852 536__ $$0G:(DE-HGF)POF3-313$$a313 - Cancer risk factors and prevention (POF3-313)$$cPOF3-313$$fPOF III$$x0
000132852 588__ $$aDataset connected to CrossRef, PubMed,
000132852 7001_ $$0P:(DE-He78)bbfe0ebad1e3b608bca2b49d4f86bd09$$aJansen, Lina$$b1$$udkfz
000132852 7001_ $$0P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aBrenner, Hermann$$b2$$eLast author$$udkfz
000132852 773__ $$0PERI:(DE-600)2046914-7$$a10.1097/DCR.0000000000001068$$gVol. 61, no. 5, p. 538 - 546$$n5$$p538 - 546$$tDiseases of the colon & rectum$$v61$$x0012-3706$$y2018
000132852 909CO $$ooai:inrepo02.dkfz.de:132852$$pVDB
000132852 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)3772dc9cbbc020fbc52b5f63f1dc1e96$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000132852 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)bbfe0ebad1e3b608bca2b49d4f86bd09$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000132852 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000132852 9131_ $$0G:(DE-HGF)POF3-313$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vCancer risk factors and prevention$$x0
000132852 9141_ $$y2018
000132852 915__ $$0StatID:(DE-HGF)0410$$2StatID$$aAllianz-Lizenz
000132852 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000132852 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bDIS COLON RECTUM : 2015
000132852 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000132852 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000132852 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000132852 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000132852 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000132852 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000132852 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000132852 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000132852 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000132852 9201_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie und Alternf.$$x0
000132852 9201_ $$0I:(DE-He78)G110-20160331$$kG110$$lPräventive Onkologie$$x1
000132852 9201_ $$0I:(DE-He78)L101-20160331$$kL101$$lDKTK Heidelberg$$x2
000132852 980__ $$ajournal
000132852 980__ $$aVDB
000132852 980__ $$aI:(DE-He78)C070-20160331
000132852 980__ $$aI:(DE-He78)G110-20160331
000132852 980__ $$aI:(DE-He78)L101-20160331
000132852 980__ $$aUNRESTRICTED